Annovis Bio, Inc. (ANVS) Financial Statements (2024 and earlier)

Company Profile

Business Address 101 LINDENWOOD DRIVE, SUITE 225
MALVERN, PA 19355
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28,377,69345,686,0148,074,658
Cash and cash equivalents28,377,69345,686,0148,074,658
Prepaid expense104,88872,84738,232
Other undisclosed current assets7,539,488242,6176,444
Total current assets:36,022,06946,001,4788,119,334
Noncurrent Assets
TOTAL ASSETS:36,022,06946,001,4788,119,334
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,698,5391,506,514574,547
Employee-related liabilities712,76816,493
Accounts payable3,961,254688,074341,856
Accrued liabilities3,737,285105,672216,198
Other undisclosed current liabilities   3,833
Total current liabilities:7,698,5391,506,514578,380
Noncurrent Liabilities
Liabilities, other than long-term debt   
Derivative instruments and hedges, liabilities   
Total noncurrent liabilities:   
Total liabilities:7,698,5391,506,514578,380
Equity
Equity, attributable to parent28,323,53044,494,9647,540,954
Common stock816810689
Additional paid in capital82,377,48873,220,36121,779,340
Accumulated deficit(54,054,774)(28,726,207)(14,239,075)
Total equity:28,323,53044,494,9647,540,954
TOTAL LIABILITIES AND EQUITY:36,022,06946,001,4788,119,334

Income Statement (P&L) (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(25,511,279)(14,537,221)(6,640,221)
Operating loss:(25,511,279)(14,537,221)(6,640,221)
Nonoperating income (expense)182,71250,0891,178,174
Investment income, nonoperating   
Interest and debt expense   (129)
Loss from continuing operations before equity method investments, income taxes:(25,328,567)(14,487,132)(5,462,176)
Other undisclosed income from continuing operations before income taxes   129
Loss from continuing operations:(25,328,567)(14,487,132)(5,462,047)
Loss before gain (loss) on sale of properties:(14,487,132)(5,462,047)
Net loss available to common stockholders, diluted:(25,328,567)(14,487,132)(5,462,047)

Comprehensive Income (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(25,328,567)(14,487,132)(5,462,047)
Comprehensive loss, net of tax, attributable to parent:(25,328,567)(14,487,132)(5,462,047)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: